"The Russian Direct Investment Fund ... announces the approval of the Russian Sputnik V vaccine against coronavirus by regulatory authorities of the Republic of Angola, Republic of Congo and Republic of Djibouti. Sputnik V has been registered under the emergency use authorization procedure," the RDIF said in a statement.
The Russian vaccine has now been approved for emergency use in 42 countries across the world.
In February, peer-reviewed medical journal The Lancet published an interim analysis from Phase III clinical trial of the Russian vaccine, showing its 91.6-percent efficacy against symptomatic COVID-19.
Developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V was the world's first officially-registered vaccine against COVID-19.